docetaxel anhydrous has been researched along with celecoxib in 38 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (47.37) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carey, RI; Dandekar, DS; Lokeshwar, BL; Lopez, M | 1 |
| Collea, R; Gajra, A; Graziano, S; Levitan, N; Marshall, J; McCann, J; Mertens, WC; Nugent, FW | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Argiris, A; Avram, MJ; Kut, V; Luong, L | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK | 1 |
| Chatterjee, A; Fulzele, SV; Shaik, MS; Singh, M | 1 |
| Miller, R; Naumovski, L; Ramos, J; Sirisawad, M | 1 |
| Chatterjee, A; Fulzele, SV; Jackson, T; Shaik, MS; Singh, M | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X | 1 |
| Albouy, B; Allain, P; Eschwege, P; Pfister, C; Rolland, F; Staerman, F; Tourani, JM | 1 |
| Bijman, MN; Boven, E; Hermelink, CA; Janmaat, ML; Laan, AC; Peters, GJ; van Berkel, MP | 1 |
| Alfaro, J; Carles, J; Catalan, G; Domenech, M; Font, A; Gallardo, E; Gonzalez Del Alba, A; González-Larriba, JL; Lianes, P; Mellado, B; Nogué, M; Tello, JM | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Chaplen, RA; Gadgeel, SM; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Schneider, BJ; Smith, DW; Worden, FP; Wozniak, AJ | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M | 1 |
| Biesma, B; Dalesio, O; Groen, HJ; Hiltermann, TJ; Hochstenbag, MM; Schramel, FM; Sietsma, H; Smit, HJ; Termeer, A; van den Berg, A; van den Borne, BE; van Putten, JW; Vincent, A | 1 |
| de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM | 1 |
| Asano, K; Ito, Y; Kim, S; Matsukawa, N; Yamamoto, K; Yamatodani, A | 1 |
| Bell, R; Khasraw, M | 1 |
| Chougule, MB; I, T; Patel, AR; Patlolla, R; Singh, M; Wang, G | 1 |
| Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY | 1 |
| Arts, H; de Munck, L; de Vries, E; Hollema, H; Hospers, G; Reyners, A; Timmer-Bosscha, H; van der Marel, P; van Kruchten, M | 1 |
| Assi, T; Bachour, M; El Rassy, E; Farhat, F; Ghosn, M; Kattan, J | 1 |
| Xie, Y; Yao, Y | 1 |
| Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG | 1 |
| Choi, HG; Hong, SS; Kim, JH; Kim, JK; Kim, JO; Kim, SY; Lim, SJ; Thapa, RK | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| Emami, J; Kazemi, M; Rezazadeh, M; Ziaei, E | 2 |
| Griebling, TL | 1 |
3 review(s) available for docetaxel anhydrous and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
17 trial(s) available for docetaxel anhydrous and celecoxib
| Article | Year |
|---|---|
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids | 2006 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazoles; Quality of Life; Sulfonamides; Taxoids; Treatment Outcome | 2007 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Taxoids | 2007 |
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazoles; Sulfonamides; Survival Rate; Taxoids | 2008 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pyrazoles; Salvage Therapy; Sulfonamides; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; France; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids; Therapeutics; Time Factors; Trastuzumab | 2010 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Quality of Life; Sulfonamides; Taxoids | 2011 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2012 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids | 2013 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Docetaxel; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Prospective Studies; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Tissue Array Analysis | 2015 |
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Docetaxel; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
18 other study(ies) available for docetaxel anhydrous and celecoxib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Bone Marrow; Carrier Proteins; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Drug Therapy, Combination; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Male; Membrane Proteins; Mice; Mice, Nude; Osteoblasts; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Stromal Cells; Sulfonamides; Taxoids; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Topics: Aerosols; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; Drug Synergism; Ethanol; Humans; Hydrocarbons, Fluorinated; In Situ Nick-End Labeling; Lung Neoplasms; Membrane Proteins; Metered Dose Inhalers; Particle Size; Polymerase Chain Reaction; PPAR gamma; Pyrazoles; RNA, Messenger; Solubility; Sulfonamides; Taxoids | 2006 |
Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; Docetaxel; Drug Synergism; Humans; Lymphoma; Metalloporphyrins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sulfonamides; Taxoids | 2006 |
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Injections, Intravenous; Interleukin-8; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Taxoids; Transplantation, Heterologous | 2006 |
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids | 2007 |
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2; DNA Adducts; Docetaxel; Drug Interactions; Extracellular Signal-Regulated MAP Kinases; Female; G2 Phase; Humans; Ovarian Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2008 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats.
Topics: Animals; Anorexia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Docetaxel; Hypothalamus; Indomethacin; Interleukin-1beta; Male; Neoplasms; Nitrobenzenes; Pro-Opiomelanocortin; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Taxoids | 2012 |
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Carriers; Gene Expression Regulation, Neoplastic; Humans; Lipids; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanostructures; Pyrazoles; Sulfonamides; Taxoids | 2013 |
Octenylsuccinate hydroxypropyl phytoglycogen, a dendrimer-like biopolymer, solubilizes poorly water-soluble active pharmaceutical ingredients.
Topics: Celecoxib; Dendrimers; Docetaxel; Fenofibrate; Glycogen; Griseofulvin; Pharmaceutic Aids; Resveratrol; Solubility; Solvents; Stilbenes; Succinates; Surface-Active Agents; Taxoids | 2018 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Role of zein incorporation on hydrophobic drug-loading capacity and colloidal stability of phospholipid nanoparticles.
Topics: Celecoxib; Colloids; Curcumin; Docetaxel; Drug Carriers; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Paclitaxel; Particle Size; Phospholipids; Surface Properties; Zein | 2018 |
Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chromatography, High Pressure Liquid; Docetaxel; Drug Monitoring; Limit of Detection; Liquid-Liquid Extraction; Male; Microspheres; Paclitaxel; Porosity; Rats; Rats, Wistar; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2020 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Pulmonary Delivery of Docetaxel and Celecoxib by PLGA Porous Microparticles for Their Synergistic Effects Against Lung Cancer.
Topics: Celecoxib; Docetaxel; Drug Carriers; Humans; Lactic Acid; Lung Neoplasms; Particle Size; Porosity | 2022 |